Polaris AI Pharma폴라리스AI파마
041910 · KOSDAQ · ₩041910 · 폴라리스AI파마
₩5,570▼ ₩110 (1.94%)End-of-day · Oct 26, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩56B | ₩60B | ₩64B | ₩62B | ₩60B |
| Cost of sales | ₩43B | ₩48B | ₩50B | ₩49B | ₩47B |
| Gross profit | ₩12B | ₩11B | ₩14B | ₩13B | ₩14B |
| Operating income | ₩3.2B | ₩176M | ₩5.3B | ₩3.2B | ₩4.3B |
| Net income | ₩6.2B | ₩3.9B | ₩3.8B | −₩6.4B | ₩5.1B |
| Net income to shareholders | ₩6.2B | ₩3.9B | ₩3.8B | −₩6.4B | ₩5.1B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩196B | ₩134B | ₩122B | ₩124B | ₩132B |
| Current assets | ₩75B | ₩78B | ₩64B | ₩68B | ₩84B |
| Cash and equivalents | ₩27B | ₩47B | ₩23B | ₩31B | ₩46B |
| Total liabilities | ₩60B | ₩5.9B | ₩6.3B | ₩8.2B | ₩11B |
| Current liabilities | ₩29B | ₩4.7B | ₩4.9B | ₩7B | ₩9B |
| Borrowings | ₩50B | — | — | — | — |
| Total equity | ₩136B | ₩129B | ₩116B | ₩116B | ₩121B |
| Shareholders' equity | ₩136B | ₩129B | ₩116B | ₩116B | ₩121B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩8.8B | ₩7.9B | ₩4.8B | −₩1.6B | ₩609M |
| Capital spending | ₩555M | ₩2.9B | ₩1B | ₩1.4B | ₩2B |
| Free cash flow | ₩8.3B | ₩5B | ₩3.8B | −₩3.1B | −₩1.4B |
| Dividends paid | ₩0 | ₩1.2B | ₩1.2B | ₩1.2B | ₩1.2B |
Consolidated where available. Amounts in won.
Also known as: Polaris AI Pharma / 폴라리스AI파마 / 041910 / KRX:041910
Source: KRX statistical information